RBC Capital raised its price target for UiPath to $19, citing stabilizing trends, while Truist Securities increased its target to $17, acknowledging the company’s strong top and bottom-line ...

Note: jsrun is under development. Expect breaking changes between minor versions. One of the most compelling use cases for jsrun is building safe execution environments for AI agents. When LLMs ...

UiPath's robotic process automation platform was under threat from AI. The company has combined the two technologies to offer a unified automation platform. UiPath is back on track and is now set to ...

In early January 2026, UiPath Inc. was added to the S&P 1000 and S&P MidCap 400 indices after reporting earnings that exceeded expectations and highlighting its progress in blending AI with robotic ...

UiPath handily beat earnings expectations and guided for strong sequential growth. The company appears to be integrating large language models into its platform in a way that's attracting customers.

Testing an AI agent for donor tissue screening at Evergen surfaces more than technical performance questions. The project reveals how documentation quality, governance, and executive discipline ...